ATP13A2
Cation-transporting ATPase 13A2
Protein Summary
ATPase that plays a role in intracellular cation homeostasis and the maintenance of neuronal integrity (PubMed:22186024). Required for a proper lysosomal and mitochondrial maintenance (PubMed:22296644, PubMed:28137957). This gene encodes a member of the P5 subfamily of ATPases which transports inorganic cations as well as other substrates. Mutations in this gene are associated with Kufor-Rakeb syndrome (KRS), also referred to as Parkinson disease 9. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Nov 2008]
- ENST00000326735
- ENSP00000327214
- ENSG00000159363
- ENST00000341676
- ENSP00000341115
- ENST00000452699
- ENSP00000413307
- PARK9
- CLN12
- KRPPD
- PARK9
- SPG78
- HSA9947
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
molecular function | 0.94 | ||
protein domain | 0.92 | ||
histone modification site profile | 0.82 | ||
kinase perturbation | 0.76 | ||
transcription factor perturbation | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 197.84 (req: < 5)
Gene RIFs: 89 (req: <= 3)
Antibodies: 178 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 197.84 (req: >= 5)
Gene RIFs: 89 (req: > 3)
Antibodies: 178 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 35
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0